Evidence map›Paper›PMID 24065545›Full record

ArticleMolecular biology reports2013

Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families.

Helena Rudnicka, Tadeusz Debniak, Cezary Cybulski, Tomasz Huzarski, Jacek Gronwald, Jan Lubinski, Bohdan Gorski

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Genes · 2021
    Article
  4. Review
  5. Complex Characterization of Germline Large Genomic Rearrangements of theInternational journal of molecular sciences · 2020
    Article
  6. Article
  7. New challenges for BRCA testing: a view from the diagnostic laboratory.European journal of human genetics : EJHG · 2016
    Review
  8. Genomic rearrangement screening of theJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2016
    Article
  9. Observational
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Helena RudnickaDepartment of Genetics and Pathology, Pomeranian Medical University, Polabska 4, 70-115, Szczecin, Poland, helena.rudnicka@pum.edu.pl.
Tadeusz Debniak
Cezary Cybulski
Tomasz Huzarski
Jacek Gronwald
Jan Lubinski
Bohdan Gorski

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRCA1 and BRCA2 are two major genes associated with familial breast and ovarian cancer susceptibility. In Poland standard BRCA gene test is usually limited to Polish founder BRCA1 mutations: 5382insC, C61G and 4153delA. To date, just a few single large genomic rearrangements (LGRs) of BRCA1 gene have been reported in Poland. Here we report the first comprehensive analysis of large mutations in BRCA1 and BRCA2 genes in this country. We screened LGRs in BRCA1 and BRCA2 genes by multiplex ligation-dependent probe amplification in 200 unrelated patients with strong family history of breast/ovarian cancers and negative for BRCA1 Polish founder mutations. We identified three different LGRs in BRCA1 gene: exons 13-19 deletion, exon 17 deletion and exon 22 deletion. No LGR was detected in BRCA2 genes. Overall, large rearrangements accounted for 3.7 % of all BRCA1 mutation positive families in our population and 1.5 % in high-risk families negative for Polish founder mutation.

Indexed as

Gene RearrangementGenetic Predisposition to DiseaseAdultBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsFamilyFemaleGenome, HumanHumansMiddle AgedOvarian NeoplasmsPolandRisk FactorsBRCA1 ProteinBRCA2 Protein

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.